METATENSIN Drug Patent Profile
✉ Email this page to a colleague
When do Metatensin patents expire, and when can generic versions of Metatensin launch?
Metatensin is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in METATENSIN is reserpine; trichlormethiazide. There are nineteen drug master file entries for this compound. Additional details are available on the reserpine; trichlormethiazide profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for METATENSIN?
- What are the global sales for METATENSIN?
- What is Average Wholesale Price for METATENSIN?
Summary for METATENSIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | METATENSIN at DailyMed |
US Patents and Regulatory Information for METATENSIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | METATENSIN #2 | reserpine; trichlormethiazide | TABLET;ORAL | 012972-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | METATENSIN #4 | reserpine; trichlormethiazide | TABLET;ORAL | 012972-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
